Avoiding Cross-Contamination in Antibiotic Manufacturing, the FDA Way

The FDA has finalized guidance on the manufacturing of antibiotics in order to prevent cross-contamination of finished pharmaceuticals and APIs with non-penicillin beta-lactam drugs.
April 24, 2013
Both penicillin and non-penicillin beta-lactam drugs can initiate drug-induced hypersensitivity reactions in some patients which can be life-threatening. Therefore the US Food and Drug Administration (FDA) has issued a series of recommendations to antibiotic manufacturers in order to minimise the risk of cross-contamination at plants that produce multiple products. Read the full story. 
Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates